Penalized drugmakers paid only 2.2% of their U.S. revenue from the drugs in question.
The analysis covers a period of the past quarter century.
Kickback penalties have not significantly impacted the financial performance of these companies.
Strategic angle: An analysis reveals that drugmakers penalized for kickbacks paid only a small fraction of their U.S. revenue from the drugs involved.
Penalized drugmakers paid only 2.2% of their U.S. revenue from the drugs in question.
The analysis covers a period of the past quarter century.
Kickback penalties have not significantly impacted the financial performance of these companies.